Protalix BioTherapeutics (NYSE:PLX) Cut to “Buy” at StockNews.com

StockNews.com lowered shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research report sent to investors on Friday morning.

Protalix BioTherapeutics Stock Performance

NYSE:PLX opened at $2.46 on Friday. The stock has a 50-day simple moving average of $1.91 and a two-hundred day simple moving average of $1.37. The firm has a market capitalization of $181.13 million, a PE ratio of -18.92 and a beta of 0.71. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $2.54.

Hedge Funds Weigh In On Protalix BioTherapeutics

Hedge funds have recently modified their holdings of the stock. PFG Investments LLC purchased a new position in shares of Protalix BioTherapeutics in the fourth quarter valued at $39,000. Cubist Systematic Strategies LLC purchased a new position in Protalix BioTherapeutics in the second quarter worth about $37,000. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics in the 3rd quarter worth approximately $36,000. Sanctuary Advisors LLC purchased a new stake in Protalix BioTherapeutics during the 3rd quarter valued at $38,000. Finally, Virtu Financial LLC bought a new stake in Protalix BioTherapeutics in the third quarter worth $44,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.